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Abstract 
Background: Onychomycosis is an infection of the nail unit by a fungus. This is a very common infection amongst 
diabetics. Its occurrence among diabetics in Fako division is unknown. In this study we provide information on the 
characteristics of onychomycosis in diabetics in Fako division, Cameroon.
Methods: A cross-sectional descriptive and analytical hospital-based study was conducted in two diabetic clinics in 
the Buea and Limbe regional hospitals. We recruited 152 consenting diabetics into the study. Demographic, behav-
ioural, and clinical data of patients were obtained through the use of structured questionnaires. Toenail, finger nail, 
skin scrapings and nail clippings were collected from participants, KOH mounts were prepared and observed under 
the microscope and cultured on Sabouraud Dextrose Agar supplemented with chloramphenicol to isolate causative 
fungi. Identification of isolates was done to species level using the cello tape flag method and slide culture. The pres-
ence of a dermatophyte by either microscopy or culture or both methods was considered positive for onychomycosis. 
Antifungal susceptibility testing was carried out using selected antifungals by the Kirby–Bauer disk diffusion method 
on Sabouraud Dextrose Agar.
Results: Clinical onychomycosis was found in 77 of the 152 diabetics tested giving a prevalence of 50.7% (95% CI 
42.4–58.9) in diabetics in Fako. No socio-demographic or clinical factor studied was significantly associated with 
onychomycosis. Trichophyton rubrum was the most common isolate (62%). Other isolates included Trichophyton meta-
graphyte (22%) and Trichophyton tonsurans (16%). Dermatophytes were sensitive to miconazole (66%), amphotericin B 
(19%) and ketoconazole (14%).
Conclusion: Onychomycosis is common in diabetics in Fako signifying the need for regular screening by either 
microscopy or culture. Infected nails could be treated with miconazole.
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Background
Onychomycosis refers to fungal infection of the nail unit 
which occurs in every part of the world. Studies have 
proven onychomycosis to be the most prevalent nail 
disease accounting for about 50% of all nail changes and 
constituting about 30% of all cutaneous fungal infections 
[1].
Diabetes mellitus (DM) is a clinical syndrome caused by 
a disorder in insulin secretion and/or action which results 
in metabolic changes, especially high blood glucose. DM 
is one of the major predisposing factors to onychomy-
cosis. Due to the rising trend in the number of people 
becoming diabetic worldwide, WHO estimated that there 
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will be 300 million diabetics by 2025 [2]. The overall risk 
ratio of diabetics having onychomycosis is 2.77 compared 
to age and sex matched non-diabetic controls [3] and the 
potential for serious sequelae is increased in diabetics 
with vascular disease of the extremity, peripheral neu-
ropathy, and those using poorly fitting shoes. Nails with 
fungal infection may become thick and distorted, some-
times with sharp edges. Such nails can abrade or ulcerate 
adjacent skin leading to severe outcomes. The abrasion or 
ulceration can increase in size, become chronic, and act 
as a portal of infection for bacteria, fungi or other organ-
isms. Impaired wound healing may result in increased 
morbidity, possible amputation of the lower extrem-
ity or even mortality. Diabetic patients with onychomy-
cosis have a higher percentage of gangrene and/or foot 
ulcer (12.2%) compared to those without onychomycosis 
(3.8%), that is a threefold higher risk [4]. Thus nail infec-
tions represent a risk factor in diabetic patients because 
of possible sequels.
Most superficial fungal infections are caused by 
keratinophilic fungi (dermatophytes). The dermatophyte 
that is mostly implicated in onychomycosis and tinea 
pedis is Trichophyton rubrum [5]. Other species that 
mostly infect the nails are Trichophyton mentagraphytes, 
Trichophyton tonsurans and Epidermophyton floccosum 
with the latter being less isolated. Both dermatophytes 
and non-dermatophytes alongside Candida albicans, 
have been identified as sole etiologic agents of onycho-
mycosis [6].
In onychomycosis, direct microscopy is the most effi-
cient screening technique [3–5]. Culture is the only 
method by which the causative microorganism can be 
identified.
There are currently three oral agents prescribed for the 
treatment of onychomycosis: fluconazole, itraconazole, 
and terbinafine. These are considered the gold standards 
in terms of cure rates, as a meta-analysis showed >70% 
success rate with these agents.
In Cameroon, like in most countries in Sub-Saharan 
Africa, diabetes is also of public health importance with 
over 567,000 (prevalence of 6.5%) persons living with the 
disease. An estimated 15,000 deaths associated with dia-
betes was recorded in the country in 2015 [7].
Although national control programmes have been put 
forth to improve on the management of diabetes, occur-
rence of onychomycosis has not been investigated in 
these patients in the country probably due to inadequate 
knowledge on the disease, poverty and limited resources. 
Thus prevalence is unknown.
It is necessary to isolate the causative agents as variabil-
ity is both geographic and, within a given region, tempo-
ral [4]. Organisms that cause clinically apparent disease 
tend to receive the most attention while pathogens whose 
invasion leads to hard-to-detect disease may be present 
in a region but are less likely to be identified.
Associated factors predisposing diabetics to onycho-
mycosis vary based on the community in which they are 
found and also the activities common in that community. 
Though certain factors may cut across regions there are 
other factors that are region specific thus providing a 
need for investigating associated factors in Fako division.
There exist high rates of recurrence of onychomycosis 
as a result of relapse due to treatment failures or re-infec-
tion [5]. As such it is of principal significance for the anti-
fungal susceptibility pattern of the isolated strains to be 
determined to reduce these high rates of recurrence and 
effective treatment of new cases.
Thus onychomycosis could be a significant cause of 
morbidity in Cameroon more especially to the vulner-
able diabetics as well as other vulnerable groups such 
as patients with human immunodeficiency virus (HIV 
patients). The findings of this study will provide useful 
information needed for a better understanding of onych-
omycosis in diabetics in Fako division and Cameroon as 
a whole.
With the goal of providing information on the char-
acteristics of onychomycosis in diabetics in Fako, we 
assessed the prevalence, associated factors, causative 




We conducted a cross-sectional descriptive and analyti-
cal hospital-based study from May to August 2014 at the 
Diabetic Clinics of the Regional hospital of Buea (RHB) 
and the Regional hospital of Limbe (RHL) found in Buea 
and Limbe respectively. Buea and Limbe constitute the 
two major cities of Fako division. These institutions serve 
as secondary referral hospitals for other hospitals and 
health institutions- public, faith based and private-in the 
region and beyond. They also serves as teaching hospi-
tals to several university related health institutions within 
the region and beyond. These hospitals receive diabetic 
patients with both Types I and II diabetes of all ages 
every day of the week but specific days of the week are 
set as clinic days with specialist consultations and patient 
education being carried out.
Participants and sampling
The study participants constituted attendants of the dia-
betic clinics of the RHB and RHL. To be eligible, par-
ticipants had to be diabetic of age 21 years or more. All 
participants were examined by a dermatologist for signs 
of onychomycosis. Participants with gestational dia-
betes, two foot amputation and those who had been on 
Page 3 of 8Eba et al. BMC Res Notes  (2016) 9:494 
antifungal treatment during the preceding four weeks 
were excluded. Convenient and consecutive sampling 
was used to select participants once they agreed to 
participate.
Data collection, variables and measurement
A structured questionnaire (see Additional file 1: Ques-
tionnaire) was used to collect data from each partici-
pant. This questionnaire was used to assess demographic 
associated factors (age, gender, diabetic clinic attended), 
behavioural factors (occupation, level of education, hob-
bies, foot wear and nail cutting habits), and clinical fac-
tors (duration of diabetes, presence of foot ulcer, other 
co-morbid disease, amputation and structural deformity, 
family history of onychomycosis, trauma, clinical mani-
festation of onychomycosis). Data collection was carried 
out by the investigator (a trained microbiologist) and this 
minimised potential bias.
Specimen collection
Nail specimens were collected from participants with 
suspected nail lesions. Severity of nail damage was clas-
sified as mild (<25% involvement or <4 nails involved), 
moderate (26–74% involvement or 5–8 nails involved) 
and severe (≥75% involvement or ≥9 nails involved). 
Where one or more of the toenails appeared clinically 
abnormal, then the two toenails that are clinically most 
likely to have onychomycosis were sampled. To obtain 
nail specimens from dystrophic nails, cleansing of the 
nail area with 90% alcohol was carried out to remove 
contaminants such as bacteria, any discoloured, dys-
trophic or brittle parts of the nail and affected nail was 
cut superficially as far back as possible using a No. 22 
surgical blade including any crumbly material. In case of 
superficial involvement (as in white superficial onycho-
mycosis) nail scrapings were collected and the free edge 
of the nail plate was also used for investigation. A sepa-
rate sample was collected if there appeared to be finger-
nail involvement as well as dermatophyte infection on 
another part of the body of any patient. Nail specimens 
were scraped directly onto black carbon papers, which 
made it easier to see how much material had been col-
lected, carefully folded and placed inside white envelopes 
and sealed providing ideal conditions for transportation 
to the laboratory. The envelopes containing samples were 
carefully labeled with patient code, age, sex, date, place 
and time of collection. Analysis was carried out within 
24 h of specimen collection.
Sample processing
Five to six small fragments (1–2  mm) or scrape mate-
rial from nails was placed on a glass slide containing a 
drop of 10% Potassium Hydroxide and glycerol (10% 
KOH + glycerol), covered with a cover-slip, gently heated 
by passing through a flame 2 or 3 times (not allowing 
solution to boil) and put aside to digest for at least 30 min 
at room temperature, then examined with ×10 and ×40 
objectives for the presence of septate fungal hyphae. 
Negative specimens were kept and re-examined the next 
day to avoid reporting false-negative results because of 
delayed clearance and as need arose some slides were 
kept till culture results became available. The glycerol 
prevented the preparation from drying off and made the 
slides still readable after several days.
Approximately 20 representative small nail fragments 
from each participant irrespective of their microscopy 
results were scattered on Sabouraud Dextrose Agar 
(SDA) plates supplemented with chloramphenicol. The 
plates were sealed with proprietary tape to prevent air-
borne contamination in the laboratory and incubated at 
room temperature (27  °C) for 7–14  days while visually 
monitoring of plate was done on a daily basis for fast 
growing fungi. Pure isolates were obtained by sub-cultur-
ing on new SDA plates and colonies growing out of the 
inoculation area were regarded as contaminants.
Identification of fungus grown on culture plates was 
based on the colony morphology, reverse pigmentation 
on SDA and the observation of sporulating fungus with 
Lactophenol cotton blue stain. Identification to species 
level was done using the cellotape flag method and the 
slide culture procedure as described elsewhere [8, 9].
Susceptibility testing was carried out using the Kirby–
Bauer disk diffusion method endorsed by the Clinical 
Laboratory Standards Institute (CLSI) [10] on dried SDA 
plates. Briefly, a tiny portion of the fungal colony was 
emulsified in 4  ml of sterile physiological saline, mixed 
and the turbidity of the suspension compared with 0.5 
McFarland standard. A sterile swab was used to streak 
the suspension on SDA plates in three directions, rotat-
ing the plate approximately 60° to ensure even distri-
bution. The isolates were tested against five antifungal 
agents including Amphotericin B (20  mcg, Biogram™), 
Ketoconazole (10 mcg Biogram™), Miconazole (50 mcg, 
Bioanalyse®), Griseofulvin (10  mcg, Bioanalyse®) and 
Itraconazole (50  mcg Bioanalyse®). After 24–48  h incu-
bation at 27  °C, the diameter of the zones of inhibition 
were measured and interpreted according to the CLSI 
criteria [10].
Data management and analysis
Questionnaire data was systematically checked for errors 
during data entry. All data obtained from the question-
naires were keyed into an Excel spread sheet (Microsoft 
Excel 2007 software) and cross checked for errors. It was 
then analyzed using the statistical package for social sci-
ences (SPSS) version 20. To assess demographic, clinical 
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and behavioral factors associated with onychomycosis, 
the logistic regression analysis was used to identify asso-
ciated factors such as age, sex, duration and type of dia-
betes, presence of co-morbid diseases and family history 
of onychomycosis, occupation, footwear, habits of nail 
cutting. Odds ratios were used to report the association 
between onychomycosis and these associated factors. 
All statistical tests used were two-tailed, and values of 
P < 0.05 were considered statistically significant.
The strobe guideline for reporting observational stud-
ies was used in writing this manuscript [11].
Results
Two hundred and twelve diabetics were approached, 
152 met the inclusion criteria and where therefore 
enrolled. The participant ages ranged from 21 to 
83  years (56.6  years ±SD  =  12.1). The greater part of 
participants (54%) were aged 50–64 years. A vast major-
ity were females (77%), 98% of study respondents were 
Type II diabetics and 49% had only a primary level of 
education.
The majority of the participants presented with mild 
nail damage 53.3% (n = 81), followed by moderate 27.6% 
(n  =  42) and severe 19.1% (n  =  29). Distal subungual 
onychomycosis was the most common clinical presen-
tation recorded in 66.2%, followed by white superficial 
onychomycosis (16.9%), total dystrophic onychomycosis 
(10.4%) and endonyx onychomycosis (6.5%).
Out of the 152 diabetics who participated in the study 
77 were confirmed for onychomycosis giving a prevalence 
of 50.7% (95% CI 42.4–58.9). Of the 77 who tested posi-
tive, 25% (n = 19) were by microscopy only, 34% (n = 26) 
by culture only and 41% (n  =  32) for both microscopy 
and culture. The prevalence amongst diabetics with dys-
trophic nails was 53% (n = 59) and 45% (n = 18) in those 
with no nail dystrophy. The prevalence of onychomyco-
sis with respect to severity of nail damage was as follows: 
mild (46.4%), moderate (64.7%) and (50%) for severe.
The association between demographic characteris-
tics and onychomycosis is shown in Table  1. No factor 
assessed was significantly associated with onychomycosis 
in multiple logistic regression analysis. Notwithstanding, 
diabetics of age >64 years were about two times as likely 
to develop onychomycosis and those who had attained 
secondary education were about two times as likely to 
develop onychomycosis than those who had attained 
only primary education(OR  =  0.61, 95% CI 0.21–1.82, 
P = 0.37).
Table  2 shows the association between clinical char-
acteristics and onychomycosis. None was statistically 
significant after multiple logistic regression analysis. 
Nonetheless diabetics with amputations and structural 
deformities were about two times as likely to develop 
onychomycosis (OR = 2.00, 95% CI 0.36–11.26, P = 0.43) 
when compared to those without.
Trichophyton species were isolated as the causative 
agents of onychomycosis in diabetics in Fako.
Trichophyton rubrum was the most common causative 
agent isolated 36 (62%) followed by T. metagraphyte 13 
(22%) and lastly T. tonsurans 9 (16%) (Fig. 1).
On the whole isolates were most sensitive to the azole 
miconazole (66%), the macrolide polyene amphotericin 
B (19%) and then the azole ketoconazole (14%). The least 
sensitive were griseofulvin (2%) and itraconazole (0%) 
(Fig. 2).
Discussion
The prevalence of onychomycosis in diabetics in Fako 
was 50.7%. This prevalence is much higher than the 30% 
reported by Bouquerra et  al. [12], in Tunisia and other 
researchers in countries where similar studies have been 
conducted [6, 13, 14]. This prevalence is nevertheless 
similar to the 50.4% obtained by Gerami et al. [15], and 
the 55% obtained by Sürücüoğlu et al. [16]. Other studies 
however indicated a higher prevalence than ours: 81% in 
Malaysia [17]. The relatively high occurrence of onycho-
mycosis recorded could be accounted for by factors such 
as background illnesses, low socioeconomic status, poor 
hygienic conditions, crowded living conditions that pro-
vide multiple opportunities for disease transmission, 
immunodeficiency, quality of education given to patients 
at treatment centers and little or no examination of dia-
betics by a dermatologist. To the best of our knowledge, 
this is the first study to be performed among diabetics 
in Cameroon; however studies performed in the gen-
eral population have revealed lower prevalence (8.8%) 
Table 1 Demographic characteristics associated with onych-
omycosis in Diabetics in Fako




 19–34 9 33.3 1.00 –
 35–49 23 47.8 1.83 (0.37–9.17) 0.46
 50–64 82 51.2 2.10 (0.49–8.97) 0.31
 >64 38 55.3 2.47 (0.54–11.37) 0.24
Sex
 Female 117 50.4 1.00 –
 Male 35 51.4 1.04 (0.49–2.22) 0.91
Educational level
 Secondary 42 40.5 1.00 –
 Primary 75 56.0 0.61 (0.21–1.82) 0.37
 Higher 16 50.0 0.90 (0.24–3.41) 0.87
 None 19 52.6 1.15 (0.42–3.14) 0.79
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of onychomycosis [18]. Studies have shown that diabetic 
patients are at a higher risk of contracting onychomyco-
sis compared to non-diabetics [4, 14]. In this study, distal 
subungual onychomycosis was observed to be the most 
common clinical presentation which is in line with stud-
ies performed elsewhere [14].
Factors associated with onychomycosis in diabetics 
identified in other studies [19–22] included sex, age, type 
and duration of diabetes, glycosylated haemoglobin lev-
els for past three months, mean glucose levels for past 
6  months, co-morbid diseases, family history, immuno-
suppressive therapy, structural amputation and deformi-
ties as well as socioeconomic status. In this study, no 
statistically significant associated factor of onchomyco-
sis in diabetics was identified. This is in agreement with 
findings made by Süheyla et al. in Turkey [23]. Nonethe-
less diabetics of age greater than 64 years were about two 
times more likely to develop onychomycosis probably due 
to repeated nail micro-trauma, a more prolonged expo-
sure to pathogenic fungi, decreased immunity, greater 
work activity and venous insufficiency. It was also noted 
that diabetics with amputations and structural deformi-
ties were about two times more likely to develop onycho-
mycosis. The observation of higher risk of onychomycosis 
in elderly diabetic patients is in line with the study by 
Sigurgeirsson and Steingrímsson [24]. The observation 
of higher risk of contracting onychomycosis in patients 
who had attained secondary education to those who had 
attained only primary education could be due to the fact 
that the majority of participants in this study were in the 
strata of secondary education.
In this study we isolated dermatophytes as the causa-
tive agents of onychomycosis with, T. rubrum being most 
prevalent followed by T. mentagrophytes and lastly T. 
tonsurans. These findings are in concordance with previ-
ous studies conducted in diabetics [13, 25]. Other stud-
ies have shown non-dermatophyte molds [26] and yeasts 
[27] as the most common causative agents of onychomy-
cosis. Studies performed on nondiabetics in other areas 
in Cameroon have reported non-dermatophytic molds 
and yeast as causative agent of onychomycosis, albeit 
lower frequency compared to dermatophytic molds [18, 
28]. This discrepancy in distribution of etiologic agents 
could be due to geographical location and a wide range 
of environmental and cultural factors such as the use of 
common bathrooms in many homes and settlements, 
weighty manual work and agricultural practises that 
bring patients in contact with the soil, organic waste and 
dirty water. Dermatophytes thrive at surface tempera-
tures of 25–28  °C and infection is supported by warm 
and high humid conditions [29]. This possibly explains 
the higher rates of infection with dermatophytes in Fako. 
Studies involving a larger number of diabetics will there-
fore be required in the study area to confirm this.
The azoles miconazole and ketoconazole were the most 
sensitive antifungals and this is in conformity with other 
studies [30, 31] that have proven desirable cure rates and 
even prevention of reoccurrence obtainable through 
the use of these drugs. In addition isolates of T. rubrum 
Table 2 Clinical characteristics associated with  clinical 
onychomycosis in diabetics in Fako
Characteristic N° tested % Positive Odds ratio (95% CI) P value
Duration of diabetes (years)
 <5 78 52.6 1.00 –
 5–10 39 46.2 0.77 (0.36–1.67) 0.51
 >10 35 51.4 0.96 (0.43–2.12) 0.91
Presence of foot ulcer
 No 150 50.7 1.00 –
 Yes 2 50.0 0.97 (0.59–5.86) 0.98
Other co-morbid disease
No 148 50.7 1.00 –
Yes 4 50.0 0.97 (0.13–7.09) 0.979
Amputation/structural deformity
 No 146 50.0 1.00 –
 Yes 6 66.7 2.00 (0.36–11.26) 0.43
Family history of onychomycosis
 No 105 50.5 1.00 –
 Yes 47 51.1 1.02 (0.51–2.04) 0.94
Nail trauma
 No 100 52.0 1.00 –
 Yes 52 48.1 0.85 (0.44–1.67) 0.646
Fig. 1 Dermatophyte distribution isolated from 58 diabetics with 
onychomycosis in Fako
Page 6 of 8Eba et al. BMC Res Notes  (2016) 9:494 
and T. metagraphyte were also sensitive to amphotericin 
B. This conflicts report given by Zaias et  al. and Gupta 
et  al. who obtained high clinical and mycological cure 
rates in patients treated with itraconazole and griseoful-
vin [29, 31]. The high resistance to itraconazole obtained 
is similar to that reported by Hryncewicz et al. [32], who 
observed resistance in 80% of isolates tested in Poland. 
High resistant rates to griseofulvin also conforms to that 
stated by Elewski who recorded high rates of resistance 
and patient relapse when treated with griseofulvin [33].
Fig. 2 Antibiotic susceptibility patterns of Trichophyton isolates from 58 diabetics in Fako division, Cameroon
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In this study we did not identify any factor associated 
with onychomycosis probably due to the relatively small 
sample size. Secondly other factors which could possibly 
influence onychomycosis as glycosylated haemoglobin 
levels for the past three months and mean glucose lev-
els for the past 6 months were not assessed. The results 
obtained from the study cannot be generalized to the 
entire Cameroon as the study was limited only to diabet-
ics in Fako division.
We suggest that further research be carried out in 
other parts of the country integrating the factors left out 
so as to establish factors common in our region and other 
regions of the country.
Conclusions
Our study suggests that approximately one out of every 
two diabetic in Fako may have onychomycosis and this 
could be detrimental to their health as it could lead to 
diabetic foot and amputations. We did not identify any 
statistically significant associated factor of onychomy-
cosis amongst this patient population. T. rubrum was 
the most common dermatophyte isolated and isolates 
were most sensitive to miconazole, amphotericin B and 
ketoconazole. All isolates of T. tonsurans and T. meta-
graphyte were completely resistant to itraconazole and 
griseofulvin.
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